GlassScriptPhysician profile
Howard Kirschen
NPI 1942261730
$2,134.62
in general payments reported to CMS, 2019-2025
17 companies · $17.91 in 2025
The $17.91 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $233 · 2021: $168 · 2022: $236 · 2023: $120 · 2024: $125 · 2025: $17.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.39 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $341.26 | 2019-2023 | Aristada, Aristada Initio |
| Neurocrine Biosciences, INC. | $257.74 | 2019-2021 | |
| Lundbeck LLC | $255.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $207.45 | 2022-2024 | |
| Allergan, INC. | $190.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $183.52 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $172.00 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.09 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $93.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $59.39 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $51.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $51.42 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Shire North American Group INC | $32.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $18.26 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $13.81 | 2020 | |
| Merck Sharp & Dohme LLC | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Kirschen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.